Ryanodine receptor Inhibitors
1 drugsAbout Ryanodine receptor
The Ryanodine receptor (RyR) is a calcium channel crucial for excitation-contraction coupling in muscle cells, regulating muscle function by controlling calcium release from intracellular stores.
RyR is a drug target in the cardiovascular therapeutic area, though currently there is no genetic evidence directly linking it to specific diseases.
RYANODEX is the only FDA-approved drug targeting RyR, developed by EAGLE PHARMS; it is a small molecule approved in 2014 with 5 indications.
Top Ryanodine receptor Drugs
EAGLE PHARMS is the only company with an approved drug targeting RyR.
Low competition suggests high barriers to entry or limited perceived market opportunity for RyR-targeting drugs.
Ryanodine receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Ryanodine receptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting RyR.
Ryanodine receptor Clinical Trials 11 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Ryanodine receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 | 100% |
| Phase 2 | 7 | 4 | 2 | 1 | 67% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Ryanodine receptor Drug Approval Timeline (2014 - 2014)
The first and only drug, RYANODEX, was approved in 2014.
The single approval in 2014 indicates potential saturation or challenges in developing further RyR-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Ryanodine receptor. A trial counts if an approved drug acting on Ryanodine receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.